Skip to content

AtriCure ATRC EPS (Diluted)

Discontinued — last reported Q1 '26

EPS (Diluted) at other companies

Abbott logo
AbbottABT
$0.61-19.7%
Johnson & Johnson logo
Johnson & JohnsonJNJ
$2.14-52.9%
Boston Scientific logo
Boston ScientificBSX
$0.90+100%
Medtronic logo
MedtronicMDT
$0.97+18.3%
ITG
Integer HoldingsITGR
$0.48+173%
Avanos Medical logo
Avanos MedicalAVNS
$0.11-21.4%

Other financials

Income statement

See full
Revenue$141.2M+14.3%
Gross profit$109.3M+18.0%
Operating income$526.0K+109%
Net income$108.0K+102%

Balance sheet

See full
Cash & equivalents$146.2M+46.3%
Total debt$76.2M-3.1%
Total equity$491.7M+8.2%
Total assets$644.0M+8.8%

Cash flow

See full
Operating cash flow-$4.0M+63.8%
CapEx$3.9M+76.6%
Free cash flow-$7.8M+40.6%

Valuation

See full
Market cap$1.43B-9.9%
Enterprise value$1.36B-13.1%
P/S2.6×-0.7×

Profitability

See full
Gross margin75.6%+0.8pp
Operating margin-5.1%-1.3pp
Net margin-5.6%-1.5pp
FCF margin9.7%

Returns & leverage

See full
Return on equity-6.1%-1.3pp
Debt / equity0.2×0.0×
Current ratio4.3×+0.2×

Where this comes from

Reported directly by AtriCure in its filing.

Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.

The official record: AtriCure’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about AtriCure's eps (diluted).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is AtriCure's EPS (diluted)?
AtriCure (ATRC) reported EPS (diluted) of $0.00 in Q1 2026.
How has AtriCure's EPS (diluted) changed year-over-year?
AtriCure's EPS (diluted) increased by 100.0% year-over-year, from -$0.14 to $0.00.
What is the long-term trend for AtriCure's EPS (diluted)?
Over 2 years (2022 to 2024), AtriCure's EPS (diluted) has grown at a -3.0% compound annual growth rate (CAGR), from -$1.01 to -$0.95.
What does EPS (diluted) mean?
Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.